Eagle Pharmaceuticals

129 articles with Eagle Pharmaceuticals

• Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference

  9/4/2018

  Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference

• Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke

  8/30/2018

  Preliminary Analysis: RYANODEX Provides Benefit for Patients

• Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies

  8/23/2018

  Achieves #1 ranking for both 3-year EPS and revenue growth

• Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA®

  8/22/2018

  BENDEKA protected by 16 patents running from 2026 through 2033

• Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results

  8/7/2018

  Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share

• Eagle Pharmaceuticals, Inc. to Discuss Second Quarter 2018 Financial Results on August 7, 2018

  7/25/2018

  Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 second quarter financial results on Tuesday, August 7, 2018, before the market opens.

• FDA Grants Eagle Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)

  7/9/2018

  Eagle Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted seven years of orphan drug exclusivity (ODE) in the U.S., for BENDEKA™ (bendamustine hydrochloride injection, or bendamustine HCI)

• Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA

  7/3/2018

  Eagle Pharmaceuticals, Inc. today announced that an additional patent has been issued related to BENDEKA® by the United States Patent and Trademark Office (USPTO).

• Court Issues Decision in Favor of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity for BENDEKA (bendamustine hydrochloride injection)

  6/11/2018

  Generic TREANDA entry now not expected until December 2022

• Eagle Pharmaceuticals, Inc. to Present at Investor Conferences in June 2018

  5/29/2018

  Eagle Pharmaceuticals, Inc. announced today that management will present at two investor conferences in June 2018.

• Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture

  5/16/2018

  Eagle to ship 500ml admixture product immediately

• Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018

  5/1/2018

  Eagle Pharmaceuticals, Inc. announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.

• Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference

  4/30/2018

  Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deutsche Bank Health Care Conferenc

• Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA

  4/16/2018

  Product is the generic version of Endo International plc’s original Vasostrict® formulation

• Eagle Pharmaceuticals Announces New Patent for Eagle Biologics

  3/27/2018

  The patent is directed to a technology that allows for the formulation of antibodies at high concentration.

• Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results

  2/26/2018

  Record 2017 revenue of $237 million

• Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Year End 2017 Financial Results on February 26, 2018

  2/16/2018

  A replay of the conference call will be available for one week after the call's completion by dialing 800-677-7320 (US) or 402-220-0666 (International) and entering conference call ID EGRXQ417.

• Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

  12/7/2017

  The Company anticipates dosing its last subject during the first half of 2018, with study completion within twelve months, and an expected NDA filing in the fourth quarter of 2018.

• Eagle Pharmaceuticals Reports Third Quarter 2017 Results

  11/8/2017

  Total revenue for the third quarter of 2017 grew 67% to $63.0 million compared to $37.8 million in the third quarter of 2016.

• Eagle Pharmaceuticals, Inc. to Discuss Third Quarter 2017 Financial Results on November 8, 2017

  10/31/2017

  Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.